Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals

Roeland E. Wasmann,1,2* Cornelis Smit,3,4 Eric P. H. van Dongen,3 Rene M. J. Wiezer,6 Jill Adler-Moore,7 Yvo M. de Beer,8 David M. Burger,1 Catherijne A. J. Knibbe,3,4 and Roger J. M. Brüggemann1,2

1Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nieuwegein, The Netherlands; 2Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein, The Netherlands; 3Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands; 4Department of Anesthesiology, Intensive Care and Pain Management, St. Antonius Hospital, Nieuwegein, The Netherlands; 5Department of Pharmacology, Leiden University, Leiden, The Netherlands; 6Department of Surgery, St. Antonius Hospital, Nieuwegein, The Netherlands; 7Department of Biological Sciences, California State Polytechnic University, Pomona, California; and 8Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center, Maastricht, The Netherlands.

In this prospective study, we examined the pharmacokinetics of 1 and 2 mg/kg liposomal amphotericin B in 16 morbidly obese individuals (104–177 kg). Body size had no effect on clearance. We recommend a fixed dose in patients ≥100 kg (ie, 300 or 500 mg rather than the current dose of 3 and 5 mg/kg, respectively).

Clinical Trials Registration. NCT02320604.

Keywords. fungal treatment; fungal infection; obese; population pharmacokinetics; optimal dosing.

Liposomal amphotericin B (L-AmB, AmBisome) is a broad-spectrum antifungal agent widely used for the treatment of invasive fungal disease. The typical dose for invasive aspergillosis is 3 mg/kg. Although L-AmB has been on the market for several decades, little is known about its pharmacokinetics in obese patients [1, 2]. This is highly relevant since the prevalence of obesity is increasing yearly and obesity is a risk factor for development of infections [3, 4]. We performed a pharmacokinetic study in morbidly obese individuals to quantify the impact of obesity on the clearance of L-AmB in order to guide dosing.

METHODS

Study Population and Procedures

We performed a pharmacokinetic study in 16 morbidly obese but otherwise healthy adults with a body mass index (BMI) >40 kg/m² the day before they underwent bariatric surgery. The study was approved by the Central Committee on Research Involving Human Subjects and conducted in accordance with the Declaration of Helsinki and good clinical practice regulations. Patients were randomly assigned to receive a single L-AmB intravenous infusion of 1 mg/kg in 0.75 hours or 2 mg/kg in 1.5 hours. Blood samples were collected 15 minutes after the end of infusion and at t = 2, 4, 6, 8, 10, 12, 24, 36, and 48 hours. Samples were centrifuged at 1900 g for 5 minutes and immediately stored at −80°C. Total AmB concentrations were measured using ultraperformance liquid chromatography with photodiode array detection, validated according to European Medicines Agency guidelines. Lower and higher limits of quantification ranged from 0.50 to 50 mg/L, and the accuracy ranged from 97.6 to 112%.

Pharmacokinetic Analysis

Concentration–time data were analyzed using nonlinear mixed effects modeling (NONMEM; v7.3.0) with Perl-speaksNONMEM (PsN; v4.7) [5]. We explored 1-, 2-, and 3-compartment models and used the first-order conditional estimation method with interaction for all model runs. Interindividual variability (IIV) was assumed to be log-normally distributed. Additive, proportional, and combined residual error models were evaluated. We investigated first-order and Michaelis-Menten elimination, and a previously reported time-dependent volume of distribution of the central compartment (Vc) was explored using an exponential-decay function. For the covariate analysis, the relationships between empirical Bayes estimates and the covariates total body weight (TBW), lean body weight [6], BMI, ideal body weight [7], body surface area [8], age, and sex were investigated in scatter plots. The performance of the final model was assessed using a prediction-corrected visual predictive check based on 1000 Monte Carlo simulations. Parameter precision and model robustness of the structural and covariate models were measured using the sampling importance resampling (SIR) procedure.

Simulations

The final model was used to simulate the area under the curve (AUC0–24h) and maximum concentration (Cmax) in steady-state conditions in 10,000 patients, with body weights uniformly distributed between 60 and 180 kg. Although normal-weight patients were not studied, we added them to the simulations to act as the comparison group with an established dose; this is justified since our model is in line with previous reports [9]. Each virtual patient received daily 3 mg/kg L-AmB infused in 1 hour; patients who weighed ≥100 kg received either 3 mg/kg or a fixed 300-mg dose. Simulating a 3-mg/kg dose is justified due to reported linear pharmacokinetics in the lower dose range.
Simulations were performed with parameter uncertainty through the stochastic simulation and estimation functionality in PsN using the SIR results as model input (n = 500 models).

RESULTS

We included 16 morbidly obese patients with median (range) BMI of 45.9 (40.2–52.1) kg/m² and TBW of 137 (104–177) kg. Other patient characteristics are summarized in Supplementary Table S1. Supplementary Figure S1 shows the observed mean plasma concentrations for each dose group.

A 2-compartment model in which no relationship could be identified between TBW and clearance was identified (Supplementary Figure S2A). A linear relationship was found between TBW and the central volume of distribution (Vc; P < .01 and there was a decrease in IIV on Vc from 17.6% to 13.8%; Supplementary Figure S2B). None of the remaining covariates further improved the model. In the final model, we found the following parameter (% IIV) estimates: clearance, 0.84 L/h (37.7%); inter-compartmental clearance, 0.61 L/h (115%); volume of distribution of the peripheral compartment, 7.3 L \( \div \) TBW / 130 (13.8%); and Vp, 12 L (22.1%); Supplementary Tables S2. Supplementary Figure S3 and S4 show that the model describes the observed data correctly and has good predictive performance. Figure 1 shows how the AUC0-24h and Cmax change with body weight (Monte Carlo simulations) when patients receive a daily 3-mg/kg L-AmB dose infused in 1 hour with and without a dose cap at 100 kg.

We identified a subgroup of 4 individuals (all received 2 mg/kg) with a significantly lower clearance and Vc and, as a consequence, a higher Cmax and AUC0-24h. No covariates (eg, size descriptors, liver or renal function tests, complete blood count, and electrolytes) could be identified that helped to explain the pharmacokinetic differences in this subgroup.

DISCUSSION

To our knowledge, this is the first study that specifically focused on the pharmacokinetics of L-AmB in morbidly obese patients. Strikingly, we found no evidence of any body size descriptor predicting differences in AmB clearance. Furthermore, we show that Vc increases linearly with TBW but is relatively small in obese patients, confirming earlier preclinical observations of a limited disposition in adipose tissue [10]. The consequence of these findings is that the AUC0-24h will increase when (obese) patients are dosed on a per-kilogram basis (Figure 1A). In parallel, Cmax also increases with body weight when L-AmB is dosed on a per-kilogram basis (Figure 1B). This phenomenon is primarily driven by the absolute increase in the dose with a clearance that does not change with weight. When using a fixed dose, Cmax decreases due to the increase in Vc with weight.

Although AUC0-24h [11] and Cmax [11, 12] have been reported to be associated with efficacy, the AUC0-24h has been associated with an increased risk of toxicity [13, 14]. To lower the potential risk of toxicity in obese patients, it seems prudent to use a fixed dose. In addition, evidence to suggest that obese patients would benefit from a higher dose is lacking; therefore, we suggest a weight of 100 kg to cap the dose (ie, 300 mg for the 3-mg/kg dose). Our simulation shows that a dose cap on 100 kg would not result in a further increase in the AUC0-24h in obese patients who weigh ≥100 kg and would also result in a similar Cmax (13% lower) in a patient who weighs 140 kg compared to 70 kg (Figure 1B).
In our study, we found an AUC$_{0-24h}$ of 279 mg*h/L after a single dose of 2 mg/kg that was much higher than the previously reported 171 mg*h/L in normal-weight healthy volunteers (median weight of 77 kg) who received the same single dose. This substantiates our results for increased exposure after weight-based dosing [15]. The absence of body weight as a covariate on clearance is in line with the findings of Würthwein et al (2012) who reported no model improvement after inclusion of body size on pharmacokinetic parameters in patients with weights ranging from 44 to 105 kg [16].

In our analyses we identified a specific subpopulation with a relatively lower clearance in half of our patients given 2 mg/kg. Several other studies also identified a subgroup with altered pharmacokinetics within their population. The data from Hope et al (2012) illustrate an almost 2-fold difference between 2 subgroups of equal size [17]. In the study by Würthwein et al (2012), use of a 3 mg/kg-dose showed higher plasma concentrations in a third of their population due to decreased clearance [16]. A third study used a model with a time-dependent decrease of $V_c$ to explain atypical pharmacokinetics in one-third of their population due to decreased clearance [16].

A potential study identified a specific subgroup with altered pharmacokinetics in one-third of their population due to decreased clearance [16]. However, our results are expected to be applicable for currently used dose regimens but should be used with caution when extrapolating to high-dose L-AmB (>5 mg/kg). Second, our study lacked a control group of normal-weight individuals. Nevertheless, our results are in line with those from the study by Würthwein et al who reported no effect of weight on clearance in patients who weighed between 44 and 105 kg, which we extend to 177 kg in our study [16]. Furthermore, the parameter estimates (%IIV) we found for clearance of 0.84 L/h (37.7%) are similar to the 0.75 L/h (55%) found in a study in normal-weight healthy volunteers. Finally, we found a high IIV on clearance, which is mainly caused by the previously mentioned subgroup. We encourage future studies to investigate this phenomena.

Based on our results, we show that body weight–derived dosing might lead to an increased risk of toxicity in obese patients as clearance and therefore exposure to AmB is not affected by body weight. In obese patients specifically, we recommend using the licensed 3 or 5 mg/kg dose and cap the dose at a maximum weight of 100 kg, resulting in a 300- or 500-mg fixed dose, respectively.

**Supplementary Data**

Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Acknowledgments.** The authors gratefully acknowledge Marijeke Versteegen and Marieke van Donkelaar for their assistance with data collection. Technical assistance was kindly provided by Arthur Pistorius.

**Financial support.** This work was supported by Gilead Sciences.

**Potential conflicts of interest.** R. J. B. has served as a consultant to Astellas Pharma, Inc, F2G, Gilead Sciences, Merck Sharp & Dohme Corp, Amphylx, and Pfizer, Inc and has received unrestricted and research grants from Astellas Pharma, Inc, Gilead Sciences, Merck Sharp & Dohme Corp, and Pfizer, Inc; all contracts were through Radboudumc, and all payments were invoiced by Radboudumc. J. A.-M. has served as a consultant to Astellas Pharma, Inc, and Gilead Sciences and has received research grants from Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome®): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 76:485–500.
2. Groll AH, Rijnders BJ, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B. Clin Infect Dis 2019; 68:260–74.
3. N. C. D. Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2415 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet 2017; 390:2627–42.
4. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6:438–46.
5. Beal S, Sheiner LB, Boekmann A, Bauer RJ. NONMEM User’s Guide. Ellicott City, MD: ICON Development Solutions, 2009.
6. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44:1051–65.
7. Pai MP, Paloucek FP. The origin of the “ideal” body weight equations. Ann Pharmacother 2000; 34:1066–9.
8. Du Bois D, Du Bois EF. Clinical calorimetry: a formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863–71.
9. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002; 46:828–33.
10. Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJ, Groll AH, Walsh TJ. Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin B. Clin Infect Dis 2019; 68:244–59.
11. Andes D, Stamsled T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45:922–6.
12. Wiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50:469–73.
13. Cornely OA, Maertens J, Bresnik M, et al; AmBLoad Trial Study Group. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBLoad trial). Clin Infect Dis 2007; 44:1289–97.
14. Lestner JM, Groll AH, Al-Jayyoussi G, et al. Population pharmacokinetics of liposomal amphotericin B in immunocompromised children. Antimicrob Agents Chemother 2016; 60:7340–6.
15. Walsh TJ, Yeldandi V, McEvoy M, et al. Safety, tolerability, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42:2391–8.
16. Würthwein G, Young C, Lanvers-Kaminsky C, et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2012; 56:536–43.
17. Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother 2012; 56:5303–8.